RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

$47.22+2.81 (+6.33%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RIGL Price Action

Last 7 days

-7.3%

Last 30 days

54.1%

Last 90 days

17.7%

Trailing 12 Months

74.6%

RIGL RSI Chart

RIGL Valuation

Market Cap

857.1M

Price/Earnings (Trailing)

7.56

Price/Sales (Trailing)

3.04

EV/EBITDA

6.5

Price/Free Cashflow

12.57

RIGL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RIGL Fundamentals

RIGL Revenue

Revenue (TTM)

282.1M

Rev. Growth (Yr)

25.59%

Rev. Growth (Qtr)

-31.69%

RIGL Earnings

Earnings (TTM)

113.3M

Earnings Growth (Yr)

124.62%

Earnings Growth (Qtr)

-53.2%

RIGL Profitability

EBT Margin

40.53%

Return on Equity

96.34%

Return on Assets

46.72%

Free Cashflow Yield

7.95%

RIGL Investor Care

Shares Dilution (1Y)

3.04%

Diluted EPS (TTM)

6.19

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	203.1M	267.9M	282.1M	0
2024	120.3M	130.3M	157.5M	179.3M
2023	129.6M	126.6M	132.4M	116.9M
2022	85.0M	88.5M	89.4M	120.2M
2021	133.9M	144.1M	147.3M	149.2M
2020	102.4M	108.0M	105.6M	108.6M
2019	57.1M	65.8M	81.7M	59.3M
2018	0	2.7M	7.6M	44.5M
2017	18.9M	10.3M	7.5M	4.5M
2016	31.7M	35.2M	25.9M	20.4M
2015	16.2M	21.4M	28.6M	28.9M
2014	0	0	0	15.4M
2013	0	2.9M	1.4M	7.2M
2012	5.7M	6.6M	2.3M	2.3M
2011	0	84.9M	44.8M	4.8M
2010	0	0	0	125.0M
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

CEO	Mr. Raul R. Rodriguez
WEBSITE	rigel.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	155

Rigel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rigel Pharmaceuticals Inc? What does RIGL stand for in stocks?

RIGL is the stock ticker symbol of Rigel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rigel Pharmaceuticals Inc (RIGL)?

As of Wed Dec 03 2025, market cap of Rigel Pharmaceuticals Inc is 857.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RIGL stock?

You can check RIGL's fair value in chart for subscribers.

Is Rigel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RIGL is over valued or under valued. Whether Rigel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rigel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RIGL.

What is Rigel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, RIGL's PE ratio (Price to Earnings) is 7.56 and Price to Sales (PS) ratio is 3.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RIGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Rigel Pharmaceuticals Inc's stock?

In the past 10 years, Rigel Pharmaceuticals Inc has provided 0.035 (multiply by 100 for percentage) rate of return.